Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Arch Therapeutics Inc (ARTH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 63,939
  • Shares Outstanding, K 163,947
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,810 K
  • 60-Month Beta -0.20
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.02
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/21/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.01
  • Number of Estimates 2
  • High Estimate -0.01
  • Low Estimate -0.01
  • Prior Year 0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3500 +11.43%
on 02/21/19
0.4200 -7.14%
on 03/12/19
+0.0040 (+1.04%)
since 02/19/19
3-Month
0.3100 +25.81%
on 02/04/19
0.5800 -32.76%
on 12/20/18
-0.1700 (-30.36%)
since 12/19/18
52-Week
0.2600 +50.00%
on 04/30/18
0.6900 -43.48%
on 06/28/18
+0.0750 (+23.81%)
since 03/19/18

Most Recent Stories

More News
OTC Markets Group Announces Gold Sponsorship of 31st Annual ROTH Conference

OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today unveiled the list of OTCQX® Best Market and OTCQB® Venture Market company presentations...

EVLLF : 0.6711 (+29.06%)
TRLFF : 0.4000 (+0.13%)
AITB : 4.6000 (-2.65%)
BICXD : 4.5400 (-9.02%)
MMNFF : 3.0200 (-1.95%)
ATEA : 5.7200 (-4.51%)
CWBHF : 18.4100 (+9.26%)
CVSI : 5.0200 (+6.58%)
DUOT : 0.6800 (unch)
CRLBF : 9.2000 (-1.08%)
ARREF : 0.8200 (unch)
CLOK : 0.9900 (+10.00%)
MLCPF : 2.5500 (-2.30%)
CNBX : 0.3841 (-2.76%)
HEOFF : 0.6188 (-4.74%)
MJARF : 2.9100 (-3.64%)
ALEAF : 1.8000 (+5.26%)
OTCM : 35.0000 (+3.35%)
NUPMF : 1.7800 (+2.30%)
GLDLF : 0.7695 (+1.38%)
NMUS : 0.6967 (+35.54%)
NLST : 0.5295 (-2.67%)
GBPT : 0.2600 (-48.00%)
IMLFF : 0.4454 (-2.11%)
KSHB : 5.6300 (-0.27%)
CORVF : 1.6500 (-1.78%)
ELLXF : 2.6600 (+4.70%)
RSSS : 2.2400 (+12.00%)
ISYRF : 1.1000 (-8.33%)
FLUX : 1.3800 (-1.43%)
NWGI : 0.3750 (-6.25%)
QBIO : 2.0520 (+4.69%)
WIZD : 0.1150 (-8.00%)
MRMD : 3.3850 (-5.97%)
GRWG : 3.0800 (-4.35%)
BRTI : 0.2412 (+0.50%)
GTBP : 0.3875 (-3.13%)
MRIC : 3.1000 (-1.59%)
DYAI : 3.1000 (+5.80%)
GTBIF : 14.0100 (+0.69%)
MTAFF : 0.9430 (+3.63%)
EMHTF : 3.4600 (+12.23%)
ITHUF : 5.5400 (-2.81%)
ALYE : 2.5000 (-16.67%)
VTLR : 0.1806 (-7.24%)
ARHH : 1.9600 (+0.51%)
OWCP : 0.0396 (+0.25%)
STLHF : 0.7180 (+0.35%)
PPCB : 0.0119 (-0.83%)
ARTH : 0.3900 (+2.63%)
ACRGF : 19.8600 (-6.54%)
Arch Therapeutics to Provide Corporate Update at the 31st Annual ROTH Conference

Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the 31 Annual ROTH...

ARTH : 0.3900 (+2.63%)
Arch Therapeutics Receives 510(k) Clearance from the US FDA for AC5(TM) Topical Gel

Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that the 510(k) premarket notification for AC5(TM)...

ARTH : 0.3900 (+2.63%)
Arch Therapeutics Provided Corporate Update at the 11th Annual LD Micro Main Event

Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, presented an update on its corporate milestones, plans and timetables...

ARTH : 0.3900 (+2.63%)
Arch Therapeutics Announces Positive Outcome of Ruling from Japanese Intellectual Property High Court

Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is pleased to announce that the Japanese Intellectual Property...

ARTH : 0.3900 (+2.63%)
Arch Therapeutics Announces Submission of CE Mark File for AC5(TM) Topical Hemostat in Europe

Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that the Company has submitted the required...

ARTH : 0.3900 (+2.63%)
Arch Therapeutics to Provide Corporate Update at the 8th LD Micro Invitational on Monday, June 4, 2018

Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the 8 LD Micro Invitational....

ARTH : 0.3900 (+2.63%)
Arch Therapeutics Provides Update on Study Initiation and 510(k)

Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, today announced that it will initiate the previously disclosed study...

ARTH : 0.3900 (+2.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade ARTH with:

Key Turning Points

2nd Resistance Point 0.4033
1st Resistance Point 0.3967
Last Price 0.3900
1st Support Level 0.3767
2nd Support Level 0.3633

See More

52-Week High 0.6900
Fibonacci 61.8% 0.5257
Fibonacci 50% 0.4750
Fibonacci 38.2% 0.4243
Last Price 0.3900
52-Week Low 0.2600

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar